Conjunctival intraepithelial neoplasia. Interferon as a rescue therapy after failure of mitomycin C

Aguiló, R.I. de la Cruz; Duch-Samper, A.; Pérez, Diego; Cotino, J. Marí

doi:10.1016/j.oftale.2014.11.001

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The security profile of IFNα2b makes it the most commonly used drug. Cases of good response to MMC after failure to IFNα2b, 12 to IFNα2b after MMC failure, 13 and to 5-FU after MMC 14, 15 have been reported. However, to date, no cases of resolution of CIN lesions with 5-FU after IFNα2b had been published.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of topical 5-fluorouracil in conjunctival intraepithelial neoplasia refractory to interferon alpha-2b

Pérez-García

Burgos-Blasco

Gómez-Calleja

et al. 2022

J Oncol Pharm Pract

View full text Add to dashboard Cite

Purpose To report the efficacy and safety of 5-fluorouracil as the second line of treatment for two cases of conjunctival intraepithelial neoplasia refractive to topical interferon alpha-2b. Case report In the first case, a 77-year-old woman was evaluated because of a fleshy vascularized lesion in the temporal conjunctiva on her right eye with leukoplakia of the corneal epithelium from 10- to 5-o’clock limbus. In the second case, an 81-year-old man, a nodular lesion in the temporal conjunctiva on his RE, with corneal adjacent opalescence, one millimeter in extent, was observed. Both patients were initially treated with excisional surgery, the samples being reported as conjunctival intraepithelial neoplasia with high-grade dysplasia. Co-adjuvant treatment with topical interferon alpha-2b 1 mIU/mL was indicated 4 times/day uninterruptedly. In the first case, there was no response despite 8 months of treatment, while in the second, the corneal lesion progressed in an arboriform pattern after 4 months of topical chemotherapy. Management & outcome In the absence of efficacy, the treatment was then changed to topical 5-fluorouracil (1%), 4 times/day for 7 days with a time-lapse of 21 days off, which constitutes a course. Two and four courses of treatment with 5-fluorouracil 1% were completed in both cases in the absence of important side effects. After the first course, both patients showed complete remission of the lesions. No clinical signs of relapse were noted after 1 year of follow-up. Discussion The treatment with 5-fluorouracil is a good option as the second line of treatment for conjunctival intraepithelial neoplasia who are low-responders to interferon alpha-2b, with fewer side effects than other currently available alternatives.

show abstract